ScholarWorks@Hanyang University: Yoon, Eileen Laurel

Detailed Information

Yoon, Eileen Laurel (윤아일린)

서울 의과대학 (DEPARTMENT OF INTERNAL MEDICINE)

Research Area: 알코올성 간질환, 비알코올성 지방간 질환, 간경변, Alcohol-related liver disease, Nonalcoholic fatty liver disease, Liver cirrhosis

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Cirrhosis:6||Metabolic syndrome:5||liver cirrhosis:5||chronic hepatitis B:5||Liver cirrhosis:4||Prognosis:4||Nonalcoholic fatty liver disease:4||acute decompensation:4||hepatocellular carcinoma:4||prognosis:3||nonalcoholic fatty liver disease:3||Nonalcoholic fatty liver disease:3||Fatty liver:3||acuteonchronic liver failure:3||mortality:3||Epidemiology:3||liver:2||advanced hepatic fibrosis:2||HBV:2||fibrosis:2||aetiology:2||Alcoholic hepatitis:2||alcoholic hepatitis:2||hepatic fibrosis:2||survival:2||hepatitis B virus:2||Nonalcoholic fatty liver:2||Acuteonchronic liver failure:2||Biomarker:2||Sorafenib:2||Nonalcoholic Fatty Liver Disease:2||MASLD:2||Chronic liver disease:2||Survival:2||magnetic resonance elastography:2||Antiviral Therapy:2||Hepatitis B:2||Liver Cancer:2||Hepatitis B Virus:2||cohort:2||Hepatitis B virus:2||Mortality:2||NA:2||NAFLD:2||Liver fibrosis:2||Hepatitis C virus:2||acute:2||FIB4:1||FIB4 Index:1||Fibrosis4 index:1||Fructose:1||Fruit:1||Functional cure:1||GGT:1||Genotype:1||HCC:1||Hepatic Fibrosis:1||Hepamet Fibrosis Score:1||Hepatic Fibrosis Burden:1||Hepatic and extrahepatic mortality:1||Hepatic artery:1||Hepatic encephalopathy:1||Hepatitis A:1||Hepatocellular Carcinoma:1||Hepatocellular carcinoma:1||Hepatorenal syndrome:1||Immunosuppression:1||Inactive Patients:1||Insulinlike growth factor binding protein 1:1||Jaundice:1||Kidney tubular necrosis:1||Korea:1||Lipocalins:1||Liver Cirrhosis:1||Liver failure:1||Liver transplantation:1||MDR:1||MLKL:1||Macrovascular Invasion:1||Maddrey's discriminant function:1||Magnetic Resonance Elastography:1||Magnetic resonance elastography:1||Metaanalysis:1||Metabolic disease:1||Metabolic dysfunctionassociated fatty liver:1||Metabolic dysfunctionassociated steatohepatitis:1||Metabolic dysfunctionassociated steatotic liver disease:1||MetabolicAssociated Fatty Liver:1||Microbiome:1||Minimal Hepatic Encephalopathy:1||NITs:1||Natural History:1||Natural killer cell:1||Necroptosis:1||Neoplasm:1||Neutrophil:1||Nonantidiabetic drugs:1||Nonalcoholic Fatty Liver:1||Noninvasive Test:1||Obesity:1||Obeticholic acid:1||Organ failure:1||Patientcentered care:1||Portal vein thrombosis:1||Prediction:1||Prophylactic:1||Psychometric Test:1||REALC:1||Randomized controlled trials as topic:1||Reactivation:1||Response:1||Risk Factor:1||Risk factor:1||SAFE score:1||Scoring system:1||Sequential organ failure assessment:1||Serum MicroRNA:1||Significant fibrosis:1||Singlenucleotide polymorphism:1||Social stigma:1||Sodium:1||Strategy:1||Stroop test:1||Sugars:1||Suicide:1||TDF:1||Tenofovir:1||Terminology:1||Transmission:1||Treatment:1||Trim22:1||Untreated patients:1||Vaccination:1||Variceal bleeding:1||Vasopressor:1||Viral hepatitis:1||Virologic Response:1||Vitamin D:1||XDR:1||advanced fibrosis:1||adverse outcomes:1||alcoholic:1||alpha fetoprotein:1||alphafetoprotein:1||angiogenesis:1||antigen:1||antiviral:1||antiviral agent:1||antiviral therapy:1||antiviral treatment:1||atrisk population:1||averagerisk population:1||bile acid toxicity:1||biomarker:1||bone density:1||cause of death:1||chronic:1||chronic liver failure:1||cirrhosis:1||cluster:1||costeffectiveness:1||decompensation:1||deep neural networking:1||diabetes:1||discontinuation:1||durability:1||educational program:1||encapsulation:1||endstage liver disease:1||entecavir:1||epsis:1||extrahepatic mortality:1||fatty liver:1||fibrosis4 index:1||gonadotropinreleasing hormone agonist:1||gut–liver axis:1||health checkup cohort:1||hepatocellular:1||hepatocyte nuclear factor 4 alpha:1||inflammation:1||lemon balm:1||linkage to care:1||lipotoxicity:1||liver cancer:1||liver failure:1||liver fibrosis:1||liver transplantation:1||macro‐:1||magnetic resonance imaging:1||mass spectrometry:1||metabolic abnormality:1||metabolic dysfunctionassociated fatty liver disease:1||metabolic dysfunctionassociated steatotic liver disease:1||mitochondria copy number:1||mitochondrial dysfunction:1||molecular:1||multidrug resistance:1||multiple reaction monitoring:1||nonalcoholic fatty liver disease fibrosis score:1||nonalcoholic steatohepatitis:1||nonalcoholic steatohepatitis:1||organ failure:1||phenotype:1||physicians:1||platelettowhite blood cell ratio:1||prediction model:1||prednisolone:1||qSOFA:1||regeneration:1||scaffold:1||screening:1||sequential therapy:1||serum biomarker:1||steatohepatitis:1||stem cell:1||tenofovir:1||tenofovir alafenamide:1||therapy:1||treatment:1||ulipristal acetate:1||unmet need:1||uterine fibroid:1||11 betaHydroxysteroid dehydrogenase type 1:1||validation:1||AARC:1||ACLF:1||ALF:1||ATP:1||Acupuncture:1||Acute decompensation:1||Acute kidney injury:1||Acuteon:1||Advanced Hepatic Fibrosis:1||Advanced fibrosis:1||Alcohol:1||Alcoholic fatty liver:1||Alcoholic liver disease:1||Alternative pathway:1||Antibiotic resistance:1||Aspartate AminotransferasetoPlatelet Ratio Index:1||Atrisk population:1||Autophagy:1||Bile acid:1||Biochemical Response:1||Biopsy:1||Carcinoma:1||Cardimetabolic:1||Cardiometabolic risk factors:1||Carnitine:1||Central obesity:1||Chemotherapy:1||Chronic:1||Clinical practice guidelines:1||Clinical trial:1||Cognitive Function:1||Comparative effectiveness:1||Complete Response:1||Complication:1||Cumulative Incidence:1||DAA:1||DNA:1||Decompensation:1||Depression:1||Deterioration:1||Diabetes:1||Dipeptidyl peptidase 4 inhibitor:1||Direct Comparison:1||ETV:1||Entecavir:1||Ethnic:1||

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE